Rechercher des projets européens

14 projets européens trouvés

Recherche sur 125080 projets européens

 TERMINÉ 

Investigating the impact of meditation training on mental health and wellbeing in the ageing population (MEDIT-AGEING)

Date du début: 1 janv. 2016, Date de fin: 31 déc. 2020,

As the number of older people in Europe grows, increasing healthy life years is a priority. Cognitive decline, dementia (e.g. Alzheimer’s disease, AD), sleep disturbances and depression, all related to psychological distress and anxiety, are significant drivers of reduced quality of life in older adults. This project builds on evidence that lifestyle factors and meditation practice have the potent ...
Voir le projet

 12

 TERMINÉ 

REgenerative Stem cell therapy for STroke in Europe (RESSTORE)

Date du début: 1 sept. 2015, Date de fin: 31 août 2020,

Stroke is the second leading cause of death in the world population. When not fatal, stroke often results in disability, due to motor and cognitive impairments, and secondary health problems affecting not only patients but also their families. Building on emerging preclinical and pilot clinical evidences, RESSTORE will focus on the clinical assessment of regenerative cell therapy to improve stroke ...
Voir le projet

 29

 TERMINÉ 

iABC Programme (IABC PROGRAMME)

Date du début: 1 août 2015, Date de fin: 31 juil. 2020,

Cystic Fibrosis (CF) is a common fatal inherited disease with a frequency of 1 in 2500 live births, affecting approximately 36,000 (0.737/10,000) people in the EU. Chronic bacterial pulmonary infection leading to an irreversible decline in lung structure and function is the main cause of mortality and morbidity in patients with CF, with more than 95% of deaths due to respiratory failure. Pseudomon ...
Voir le projet

 21

 TERMINÉ 

Efficacy and safety of MRI-based thrombolysis in wake-up stroke: a randomised, double-blind, placebo-controlled trial (WAKE-UP)

Date du début: 1 déc. 2011, Date de fin: 30 nov. 2017,

WAKE-UP is an investigator-initiated, multicentre, randomised, double-blind, placebo-controlled trial designed to test efficacy and safety of MRI-based intravenous thrombolysis in patients with wake-up stroke. Every year 1.5 million patients suffer a stroke in the EU. Up to 20% of stroke patients wake up with stroke symptoms. Currently these patients are excluded from thrombolysis which is the onl ...
Voir le projet

 13

 TERMINÉ 

Cystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in Exacerbations: Results Stratified (CFMATTERS)

Date du début: 1 oct. 2013, Date de fin: 30 juin 2017,

Antimicrobial resistance is arguably the most significant challenge facing the EU health care system. The unnecessary use of antibiotics is a key driver in the development of antibiotic resistance. Cystic Fibrosis (CF) represents a unique disease model to study bacterial resistance and to explore therapeutic strategies for same, as chronic lung infection overlaps with acute lung exacerbations caus ...
Voir le projet

 15

 TERMINÉ 

Clinical European study on the outcome of surgical and hormonal therapy and psychological intervention in disorders of sex development (DSD) (DSD-LIFE)

Date du début: 1 oct. 2012, Date de fin: 31 mars 2017,

Disorders of sex development (DSD) are a conglomerate of rare diseases with an estimated incidence of 1: 4500. The causes of DSD are mainly disorders with gonadal dysgenesis, decreased androgen synthesis or function in XY males or disorders with elevated androgen production in XX females. Decision on sex of rearing is difficult in some cases as the prenatal androgen imbalances result in ambiguous ...
Voir le projet

 17

 TERMINÉ 

European Modular Education and Training Programme in Safety Sciences for Medicines (SAFESCIMET)

Date du début: 1 janv. 2010, Date de fin: 30 nov. 2016,

Background:In current drug safety education and training in Europe, an integrative and translational approach is lacking. This shortfall has been identified by EUFEPS. The IMI (‘Strategic Research Agenda’), the FDA and the EMEA have also characterised this fact as a crucial gap in the education and training of scientists evaluating the safety of drug candidates and new medicines. Scope and objecti ...
Voir le projet

 34

 TERMINÉ 

Biopharmaceutical therapy for treatment of Primary Hyperoxaluria (ELIMOX)

Date du début: 1 oct. 2013, Date de fin: 30 sept. 2016,

"Interest in the use of naturally occurring human gut bacteria as pharmaceutical drugs has increased as knowledge about the human microbiota and its role in health and disease has advanced.The ELIMOX project proposes to develop a new drug from Oxalobacter formigenes, an anaerobic bacterium whose only carbon source is oxalate, for the treatment of primary hyperoxaluria (PH). PH is a rare and life-t ...
Voir le projet

 12

 TERMINÉ 

Clinical development of Enzyme Replacement Therapy in alpha-Mannosidosis patients using recombinant human enzyme (ALPHA-MAN)

Date du début: 1 oct. 2010, Date de fin: 31 mars 2014,

Alpha-Mannosidosis is a rare Lysosomal Storage Disorder with a worldwide incidence of about 1:500 000. This orphan and devastating disease is caused by the deficiency of the lysosomal alpha-mannosidase (LAMAN) which is responsible for the intralysosomal degradation of mannosyl linked oligosaccharides. To date no causative treatment for alpha-Mannosidosis is available and since most of the children ...
Voir le projet

 12

 TERMINÉ 

EUropean Research initiative to develop Imaging Probes for early In-vivo Diagnosis and Evaluation of response to therapeutic Substances (EURIPIDES)

Date du début: 1 févr. 2008, Date de fin: 31 juil. 2012,

"We aim develop in-vivo imaging biomarker of multidrug transporter function as a generic tool for the prediction, diagnosis, monitoring and prognosis of major CNS diseases, as well as to provide support and guidance for therapeutic interventions. Multidrug transporters actively transport substrates (including multiple CNS drugs) against concentration gradients across the blood-brain barrier (BBB). ...
Voir le projet

 14

 TERMINÉ 

Development of 6-mercaptopurine and Methotrexate oral liquid formulations for the maintenance treatment of Acute Lymphoblastic Leukæmia in children (LOULLA&PHILLA)

Date du début: 1 nov. 2008, Date de fin: 30 avr. 2012,

"Only for Children Pharmaceuticals, a French based Small and Medium-sized Enterprise (SME) developing drug for children, is the Coordinator of a multinational, multidisciplinary and complementary Consortium. This Consortium is composed of highly qualified organizations and notorious clinicians in pediatric hemato-oncology. The Consortium is an integrated team of competencies (clinicians, pædiatric ...
Voir le projet

 12

 TERMINÉ 

Mitochondrial dysfunction in neurodegenerative diseases: towards new therapeutics (Mitotarget)

Date du début: 1 févr. 2009, Date de fin: 31 mars 2012,

Mitochondrial dysfunction is a major hallmark of various neurodegenerative disorders including Alzheimer’s disease, Parkinson’s disease, Huntington’s diseases or Amyotrophic Lateral Sclerosis (ALS). However linking mitochondrial dysfunction to the pathogenesis of some of these diseases still needs to be elucidated. Furthermore, in pathologies where this link is already established, the question re ...
Voir le projet

 19

 TERMINÉ 

Investigation of the molecular pathogenesis and pathophysiology of Disorders of Sex Development (DSD) (EuroDSD)

Date du début: 1 mai 2008, Date de fin: 31 oct. 2011,

Disorders of Sex Development (DSD) constitute a group of rare to very rare mostly heritable disorders affecting the genito-urinary tract and in most instances also the endocrine-reproductive system. We hypothesize that stringent and stepwise analysis of cases with DSD will result in a systematic and reliable discovery of DSD-relevant biochemical, genetic and functional profiles, allowing for the d ...
Voir le projet

 14

 TERMINÉ 

"European Networks of Centres of Expertise for CF (Cystic Fibrosis), LAM (Lymphangioleiomyomatosis), and LTX (Lung Transplantation)" (ENCE-CF-LAM-LTX)

Date du début: 1 avr. 2009, Date de fin: 31 mars 2011,

"European Centres of Expertise Networks for rare diseases have been identified by the European Commission as one important area of future activity in the attempt of achieving one of the main objectives across the EC endeavour of “Optimising the delivery of health care to European Citizens”. It is obvious that especially in rare diseases the joined forces of the experts networking throughout Europe ...
Voir le projet

 8